GET DAILY SIGNALSHealthStream (HSTM) Delivers Revenue Beat and Raises 2026 Guidance in Q3
Key Takeaways
- HealthStream reported third quarter 2026 revenue of $83.3 million, up 8.9% year over year and above analyst expectations.
- Diluted earnings per share (EPS) came in at $0.18, topping consensus estimates even as it declined from $0.20 a year earlier.
- Operating income fell 13.0% to $6.6 million, reflecting higher spending on personnel, cloud hosting, and platform investments.
- Management raised its full-year 2026 guidance, citing sustained revenue momentum across its clinical workforce solutions.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose modestly to $19.3 million from $19.1 million.
- For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
- Discover automated strategies and market signals by exploring Trending AI Robots.
Why These Results Matter
HealthStream runs one of the larger SaaS platforms in healthcare for workforce training, credentialing, and scheduling. Its quarterly numbers give a window into how hospitals are allocating resources for clinical staff development at a time when staffing challenges remain significant. The third quarter represents the first full period incorporating the two acquisitions closed in late 2025, so it provides an early look at integration progress alongside ongoing organic growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Rising operating costs tied to platform investments are another focus, even with the raised outlook.
Q3 Results in Detail
For the quarter ended September 30, 2026, HealthStream posted net revenues of $83.3 million, an 8.9% rise from $76.5 million in the same period last year and ahead of estimates around $82 million. Subscription revenue increased $6.2 million, or 8.0%, while professional services added $0.7 million. Roughly $3.2 million of the growth came from the Virsys12 and MissionCare Collective acquisitions, with about $3.6 million from organic sources.
Diluted EPS reached $0.18, beating expectations though down from $0.20 a year ago. Net income dropped 11.7% to $5.4 million, and operating income declined 13.0% to $6.6 million amid higher personnel, third-party software, cloud hosting, and amortization expenses. The quarter included roughly $250,000 in net costs related to a July 2026 cybersecurity incident.
Adjusted EBITDA edged up 1.0% to $19.3 million from $19.1 million. Management lifted full-year 2026 revenue guidance to $331 million–$333 million and net income guidance to $21.8 million–$22.4 million.
Market Reaction and Balance Sheet Strength
Investor sentiment had been positive heading into the report, with HealthStream shares up about 49% year to date and more than 20% over the past three months. The stock closed near $34.58 before the release. The revenue beat and raised guidance support the growth story, yet the year-over-year drop in operating and net income highlights questions about whether added spending will lead to better operating leverage. The balance sheet offers reassurance, with $115.2 million in cash and marketable securities and no debt from borrowings; a $40 million private placement in September added capital for strategic moves.
What Investors Should Watch Next
Attention will center on whether the Virsys12 and MissionCare Collective deals keep contributing revenue while organic growth holds steady. The decision to raise guidance points to durable demand, but the split between acquisition and organic contributions will be key for assessing top-line sustainability. On costs, it will be worth monitoring whether personnel, third-party software, and cloud hosting expenses ease. Higher operating costs pressured income this quarter, and signs that these investments are boosting retention or new bookings could reduce margin concerns. Cybersecurity expenses and any follow-on effects from the July incident also merit watching, given the importance of data security for a healthcare-focused SaaS provider.
Enhancing Analysis with AI Tools
When reviewing names like this one, I often rely on Tickeron’s AI tools to quickly surface comparable ideas and track technical patterns alongside fundamentals. The AI Screener has been particularly useful for filtering opportunities across industries in a single view. It supports customizable scans on market cap, volatility, and performance metrics, which helps me stay efficient without replacing my own judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HSTM sees MACD Histogram crosses below signal line
HSTM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 54 instances where the indicator turned negative. In 29 of the 54 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 54%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for HSTM moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 9 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 38%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 58 cases where HSTM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
HSTM broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on HSTM as a result. In 60 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
Following a +4.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where HSTM advanced for three days, in 169 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 122 of 201 cases where HSTM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. HSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.967) is normal, around the industry mean (4.699). HSTM has a moderately high P/E Ratio (48.028) as compared to the industry average of (13.248). Projected Growth (PEG Ratio) (2.857) is also within normal values, averaging (2.133). Dividend Yield (0.004) settles around the average of (0.011) among similar stocks. P/S Ratio (2.711) is also within normal values, averaging (6.065).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of SaaS-based workforce development, research, patient experience solutions
Industry ServicestotheHealthIndustry
Advertisement